Quality of life (change from baseline) in the medium term · patients with schizophrenia or related psychoses
1 finding from 1 review
Impact of interventions for stuttering on emotional, cognitive and psychosocial domains, or quality of life · children aged six years and younger who stutter
1 finding from 1 review
Quality of life (measured using EORTC QLQ‐BLS24 at baseline and after each installation weekly for 6 weeks)
1 finding from 1 review
Health‐related quality of life measured using QUALID (12–45, higher score indicates poorer quality of life) · people with dementia
1 finding from 1 review
Health‐related quality of life measured using QUALID (12–45, higher score indicates poorer quality of life) · people with dementia
1 finding from 1 review
Intervention not reported
Quality of Life EORTC European Organisation for Research and Treatment of Cancer ‐ Global Scale from: 0‐100 · breast cancer survivors
1 finding from 1 review
QoL · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
QoL · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
IBDQ at week 8 · people with inflammatory bowel disease
1 finding from 1 review
Intervention not reported
HRQoL Using EQ‐5D (range 0 to 1) and HOOS (range 0 to 100). A higher score indicates better quality of life. · adults following hip fracture surgery
It is very uncertain whether the intervention changes HRQoL Using EQ‐5D (range 0 to 1) and HOOS (range 0 to 100). A higher… (very low certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Health‐related quality of life Dementia‐specific quality of life measure (QUALIDEM) (higher scores = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings
1 finding from 1 review
no estimate extracted
33 participants
Very low
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Disease‐specific quality of life · children with obstructive sleep‐disordered breathing
1 finding from 1 review
Intervention not reported
Quality of Life SF‐36 Physical Summary score (scale 0 to 100, higher score indicates better quality of life) · adults with intermittent claudication
1 finding from 1 review
QoL · people with inflammatory bowel disease
1 finding from 1 review